RxDoctor Payments Data

Katherine Flynn, MD

Optometrist · Tarpon Springs, FLNPI 1396794715

Payments from drug & device makers

$3,448in general payments, 2019–2025

Across 98 payments — averaging $35.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$593
  • Alcon$423
  • Bausch & Lomb Americas Inc.$415
  • AbbVie$400
  • Oyster Point Pharma, Inc.$257
  • Amgen$207
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,448 in reported general payments places this provider in the 80th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$134,895
Medicare patients
702
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine197$223,335
MieboPerfluorohexyloctane/Pf41$59,877
XdemvyLotilaner29$53,612
XiidraLifitegrast46$34,437
LumiganBimatoprost72$33,101
TyrvayaVarenicline Tartrate23$18,088
CequaCyclosporine13$12,371
Cyclosporine17$9,111
Lotemax SmLoteprednol Etabonate30$7,510
Tobradex StTobramycin/Dexamethasone27$6,523
Prednisolone Acetate26$779
Latanoprost77$678
Brimonidine Tartrate22$678
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$403
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$400$256,436269 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$415$94,31587 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$156$53,61229 claims
Oyster Point Pharma, Inc.Tyrvaya$257$18,08823 claims
Sun Pharmaceutical Industries Inc.Cequa$593$12,37113 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$200$7,51030 claims
Eyevance Pharmaceuticals LLCTobradex St$22$6,52327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Tarpon Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →